Person: YAMAÇ, AYLİN HATİCE
6 results
Search Results
Now showing 1 - 6 of 6
Publication Metadata only Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results(2015-10-01T00:00:00Z) Goktekin, Omer; YAMAÇ, AYLİN HATİCE; Latib, Azeem; Tastan, Ahmet; Panoulas, Vasileios F.; Sato, Katsumasa; Erdogan, Ercan; Uyarel, Huseyin; Shah, Ibrahim; Colombo, Antonio; YAMAÇ, AYLİN HATİCEAims. The bioresorbable vascular scaffold (BVS) (Abbott Vascular) provides temporary scaffolding while eluting everolimus. There are limited data on its use in daily practice, especially in patients with stable angina pectoris referred for elective percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs). The current study aims to investigate the safety and efficacy of BVS implantation in a selected patient cohort with CTO. Methods. A total of 70 consecutive patients, who underwent successful recanalization of CTO with BVS between September 13, 2012 and September 20, 2014 in three cardiac centers (Department of Cardiology, Bezmialem Vakif University, Istanbul, Turkey; Department of Interventional Cardiology, San Raffaele Hospital, Milan, Italy; and EMO-GVM Centro Cuore Columbus, Milan, Italy) were included in this CTO registry. Endpoints analyzed included: (1) the composite of all-cause death and non-fatal myocardial infarction (MI); and (2) the composite safety endpoint of major adverse cardiovascular events (MACEs), including death, MI and symptom-driven target lesion revascularization (TLR). Results. Clinical data were obtained for 70 patients (mean age, 56.9 +/- 9.4 years; 90.0% male) with a total number of 76 CTOs. At a median follow-up of 11.0 months (interquartile range, 7-18 months), both MACE and TLR rates were 4.3%. Two patients suffered from ischemia-driven TLR (1 patient at 6 months and 1 patient at 9 months after implantation). No death, MI, or stent thrombosis was observed during the follow-up period. Conclusion. Treatment of CTOs with BVS seems to be safe and effective, with a high technical success rate and acceptable MACE at short-term follow-up.Publication Open Access Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS-STEMI COVID-19 Registry(2022-11-01) De Luca G.; Algowhary M.; Uguz B.; Oliveira D. C.; Ganyukov V.; Zimbakov Z.; Cercek M.; Jensen L. O.; Loh P. H.; Calmac L.; et al.; YAMAÇ, AYLİN HATİCEThe so-called \"smoking paradox\", conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS-STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization (p < 0.001), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers (p < 0.001); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital (p < 0.001) and 30-day (p < 0.001) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.Publication Metadata only Comparison of the transradial and transfemoral approach in treatment of chronic total occlusions with similar lesion characteristics(2018-05-01T00:00:00Z) HUYUT, MUSTAFA AHMET; YAMAÇ, AYLİN HATİCE; HUYUT, MUSTAFA AHMET; YAMAÇ, AYLİN HATİCEObjective: There is limited data on the efficacy and the safety of the transradial approach (TRA) for percutaneous coronary intervention (PCI) of chronic total occlusion (CTO), particularly in comparison with the transfemoral approach (TFA) in lesions with similar complexity.Publication Open Access Outcomes in Coronary No Reflow Phenomenon Patients and the Relationship between Kidney Injury Molecule-1 and Coronary No-Reflow Phenomenon(2021-02-01T00:00:00Z) Huyut, Mustafa Ahmet; YAMAÇ, AYLİN HATİCE; YAMAÇ, AYLİN HATİCEBackground: Coronary no-reflow phenomenon (CNP) is associated with an increased risk of major cardiovascular adverse events (MACE).Publication Metadata only MicroRNA 199a Is Downregulated in Patients After Coronary Artery Bypass Graft Surgery and Is Associated with Increased Levels of Sirtuin 1 (SIRT 1) Protein and Major Adverse Cardiovascular Events at 3-Year Follow-Up(2018-09-01T00:00:00Z) YAMAÇ, AYLİN HATİCE; Bakhshaliyev, Nijad; HUYUT, MUSTAFA AHMET; Yilmaz, Emre; ÇELİKKALE, İLKE; BACAKSIZ, AHMET; Demir, Yusuf; Demir, Ali Riza; Erturk, Mehmet; ÖZDEMİR, Ramazan; KILIÇ, ÜLKAN; YAMAÇ, AYLİN HATİCE; HUYUT, MUSTAFA AHMET; ÇELİKKALE, İLKE; BACAKSIZ, AHMET; BAKHSALIYEV, NIJAD; ÖZDEMİR, RAMAZANBackground: The cardioprotective protein SIRT1 is elevated in patients with coronary artery disease (CAD) to compensate for the disease-related adverse effects, but less is known about the prognostic role of SIRT 1 regulating microRNAs in patients after coronary artery bypass graft (CABG) surgery.Publication Metadata only Effect of statins on sirtuin 1 and endothelial nitric oxide synthase expression in young patients with a history o f premature myocardial infarction(2018-04-01T00:00:00Z) YAMAÇ, AYLİN HATİCE; KILIÇ, ÜLKAN; YAMAÇ, AYLİN HATİCEObjective: The present study was an investigation of the effect of statins on the expression of circulating sirtuin 1 (SIRT1) and endothelial nitric oxide synthase (eNOS) proteins, and on the distribution of single nucleotide polymorphisms (SNPs) of the SIRT1 gene in patients with a history of premature myocardial infarction (PMI).